Neurocrine Biosciences
NBIX
#1290
Rank
โ‚น1.169 T
Marketcap
โ‚น11,549
Share price
0.34%
Change (1 day)
14.66%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of September 2024 : โ‚น21.43 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is โ‚น21.43 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31โ‚น35.66 B63.93%
2022-12-31โ‚น21.75 B-33.63%
2021-12-31โ‚น32.77 B8.71%
2020-12-31โ‚น30.15 B-14.66%
2019-12-31โ‚น35.33 B30.08%
2018-12-31โ‚น27.16 B15.1%
2017-12-31โ‚น23.60 B
2009-12-31โ‚น0.53 B-27.71%
2008-12-31โ‚น0.74 B1169%
2007-12-31โ‚น58.31 M-97.55%
2006-12-31โ‚น2.37 B-11.13%
2005-12-31โ‚น2.67 B-6.66%
2004-12-31โ‚น2.86 B72.64%
2003-12-31โ‚น1.65 B335.93%
2002-12-31โ‚น0.38 B38.67%
2001-12-31โ‚น0.27 B51.92%
2000-12-31โ‚น0.18 B34.02%
1999-12-31โ‚น0.13 B5.65%
1998-12-31โ‚น0.12 B102.86%
1997-12-31โ‚น62.87 M9.32%
1996-12-31โ‚น57.52 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
โ‚น57.34 B 167.49%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น648.75 B 2,926.01%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น40.12 M-99.81%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น2.653 T 12,278.56%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น6.061 T 28,173.27%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.681 T 26,398.41%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น53.33 B 148.75%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.58 B-92.61%๐Ÿ‡บ๐Ÿ‡ธ USA